Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call Transcript

Operator

Good day, and welcome to the Hansa Biopharma Fourth Quarter and Full-Year 2025 Financial Results Conference Call. [Operator Instructions]. Please note that this event is being recorded.

I would now like to turn the conference over to Hansa Biopharma’s CEO, Renee Aguiar-Lucander. Please go ahead.

Renee Aguiar-Lucander
Chief Executive Officer

Thank you. Good afternoon, and good morning. Welcome to the Hansa Biopharma conference call to review Q4 and the results for the full-year of 2025. I’m Renee Aguiar-Lucander, CEO of Hansa Biopharma. Joining me today is Evan Ballantyne, Chief Financial Officer; Richard Philipson, Chief Medical Officer; and Maria Tornsen, Chief Operating Officer and President, U.S.

Please turn to Slide 2. Please allow me to draw your attention to the fact we’ll be making forward-looking statements during this presentation, and you should therefore apply appropriate caution. Please turn to Slide 3 and today’s agenda.

Let’s move on to Page 4, please. In terms of key achievements in Q4, Q4 saw strong growth over the same quarter last year, with product revenue growth of almost 140% and total revenue growth of 135%. Total revenues for the year amounted to SEK 222.3 million or about $25 million, a growth of 46% compared to total revenues in 2024. In Q4, we successfully also closed an equity round of SEK 671.5 million or about USD 71 million, which will fund operations into 2027.